To evaluate the implementation and accuracy of combination biopsies (cBx) in a nationwide setting and compare their detection rates of clinically significant prostate cancer to systematic biopsies (sBx).
Key Findings:
67% of men diagnosed with prostate cancer had either cBx or standalone sBx, indicating a high detection rate.
Concordance between tBx and sBx in cBx was moderate (0.67), while concordance with RP pathology was weak (0.53).
54% of cases showed unchanged GG from cBx to RP, with downgrading in 21% and upgrading in 25% of cases.
Interpretation:
The study suggests that while cBx shows moderate agreement between biopsy strategies, its weak concordance with RP pathology indicates potential limitations in accuracy and may affect treatment decisions.
Limitations:
The study only included men undergoing their first biopsy, which may not represent all prostate cancer cases and could introduce selection bias.
Exclusion of men who migrated may limit the generalizability of the findings.
Conclusion:
Combination biopsies may improve detection rates of clinically significant prostate cancer, but further evaluation is needed to understand their impact on treatment outcomes and patient management.
